In short
A new clinical trial is exploring an innovative approach to treating metastatic fusion-driven sarcomas in children and young adults. This phase I/II trial focuses on using a personalized peptide vaccine called IPX vaccine, which contains PERVI-FUS, PERVI-NEO, and 11902A. The study aims to assess the vaccine's ability to induce T-cell responses in patients with Ewing sarcoma, alveolar rhabdomyosarcoma, or synovial sarcoma who have achieved complete remission or partial response after standard treatment.
At a glance
- Trial Type
- Phase I/II
- Target Population
- Children and young adults (2-40 years) with metastatic fusion-driven sarcomas
- Specific Cancer Types
- Ewing sarcoma, alveolar rhabdomyosarcoma, synovial sarcoma
- Treatment
- Personalized peptide vaccine (IPX vaccine) containing PERVI-FUS, PERVI-NEO, and 11902A
- Primary Objective
- Assess vaccine-induced T-cell response
- Secondary Objectives
- Evaluate feasibility, safety, and early efficacy data
- Dosage
- Maximum daily dose: 0.3 mg; Maximum total dose: 0.9 mg
- Treatment Duration
- Up to 113 days
- Key Eligibility
- Complete remission or partial response after standard treatment, specific genetic testing required
What is the IPX Vaccine?
The IPX vaccine is an innovative, personalized peptide vaccine being studied for the treatment of certain types of metastatic sarcomas in children and young adults. This vaccine is unique because it is tailored to each individual patient, using specific proteins (peptides) that are designed to target their particular cancer.
The IPX vaccine contains three main components: PERVI-FUS: A peptide targeting fusion proteins in the cancer cells PERVI-NEO: A peptide targeting new (neo) proteins in the cancer cells 11902A: An additional component that may help boost the vaccine's effectiveness
Target Medical Conditions
The IPX vaccine is being studied for patients with specific types of metastatic sarcomas. These are cancers that have spread from their original location to other parts of the body. The trial focuses on three types of fusion-driven sarcomas: Ewing sarcoma: A rare type of cancer that occurs in bones or in the soft tissue around the bones Alveolar rhabdomyosarcoma: A type of soft tissue cancer that develops in muscle tissue Synovial sarcoma: A rare type of cancer that typically occurs near the joints of the arm, neck, or leg These cancers are called "fusion-driven" because they are caused by the abnormal fusion of genes, which leads to the production of abnormal proteins that drive cancer growth.
How the IPX Vaccine Works
The IPX vaccine is designed to stimulate the patient's immune system to recognize and attack cancer cells. Here's how it works: Scientists analyze the patient's cancer cells to identify specific abnormal proteins (peptides) that are unique to their cancer. These peptides are then manufactured into a personalized vaccine. When injected, the vaccine trains the patient's immune system to recognize these cancer-specific peptides as foreign. The goal is for the immune system to then attack and destroy cancer cells that have these specific peptides, potentially preventing or delaying cancer recurrence.
Current Clinical Trial
The IPX vaccine is currently being studied in a Phase I/II clinical trial. This means it's in the early stages of research in humans. The main goals of this trial are: To assess if the vaccine can induce an immune response against the cancer cells To evaluate the safety and tolerability of the vaccine To gather early data on how effective the vaccine might be in preventing cancer recurrence
Who Can Participate in the Trial?
The trial is designed for specific patients. Some key eligibility criteria include: Patients aged 2-40 years with metastatic Ewing sarcoma, alveolar rhabdomyosarcoma, or synovial sarcoma Patients who have achieved complete remission or partial response after standard treatment Availability of genetic data about the patient's tumor There are also several exclusion criteria, such as certain medical conditions or treatments that might interfere with the study.
Safety Considerations
As with any medical treatment, safety is a crucial consideration. The trial carefully monitors for any side effects or adverse reactions to the vaccine. Patients with certain conditions, such as uncontrolled seizures, severe autoimmune diseases, or recent use of live vaccines, may not be eligible for the trial due to safety concerns.
Potential Benefits
While it's important to note that the IPX vaccine is still in the research phase, the potential benefits being studied include: Stimulation of the immune system to fight against cancer cells Possible prevention or delay of cancer recurrence A personalized approach to cancer treatment The trial will measure outcomes such as immune response, event-free survival, and overall survival to assess these potential benefits.